Build Your Comparison

Side-by-side financial analysis
TIL logo
TIL
TMO logo
TMO
ILMN logo
ILMN
DHR logo
DHR
A logo
A
Try popular comparisons:

Stock Comparison

TIL vs TMO vs ILMN vs DHR vs A

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TIL
Instil Bio, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$54M
5Y Perf.-98.4%
TMO
Thermo Fisher Scientific Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$174.42B
5Y Perf.+2.8%
ILMN
Illumina, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$24.45B
5Y Perf.-56.9%
DHR
Danaher Corporation

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$127.47B
5Y Perf.-9.7%
A
Agilent Technologies, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$36.67B
5Y Perf.+2.1%

TIL vs TMO vs ILMN vs DHR vs A — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TIL logoTIL
TMO logoTMO
ILMN logoILMN
DHR logoDHR
A logoA
IndustryBiotechnologyMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$54M$174.42B$24.45B$127.47B$36.67B
Revenue (TTM)$0.00$45.20B$4.39B$24.78B$7.23B
Net Income (TTM)$-47M$6.86B$853M$3.69B$1.41B
Gross Margin39.4%67.1%60.7%53.0%
Operating Margin17.8%20.9%21.0%21.5%
Forward P/E18.9x30.8x21.3x21.4x
Total Debt$85M$40.85B$2.55B$18.42B$3.35B
Cash & Equiv.$7M$9.86B$1.42B$4.62B$1.79B

TIL vs TMO vs ILMN vs DHR vs ALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TIL
TMO
ILMN
DHR
A
StockMar 21Jun 26Return
Instil Bio, Inc. (TIL)1001.6-98.4%
Thermo Fisher Scien… (TMO)100102.8+2.8%
Illumina, Inc. (ILMN)10043.1-56.9%
Danaher Corporation (DHR)10090.3-9.7%
Agilent Technologie… (A)100102.1+2.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: TIL vs TMO vs ILMN vs DHR vs A

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ILMN and DHR are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Danaher Corporation is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. TIL, TMO, and A also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
TIL
Instil Bio, Inc.
The Growth Leader

TIL ranks third and is worth considering specifically for growth.

  • 37.2% revenue growth vs ILMN's -0.8%
Best for: growth
TMO
Thermo Fisher Scientific Inc.
The Long-Run Compounder

TMO is the clearest fit if your priority is long-term compounding.

  • 219.0% 10Y total return vs DHR's 222.6%
  • Lower P/E (18.9x vs 30.8x)
Best for: long-term compounding
ILMN
Illumina, Inc.
The Momentum Pick

ILMN has the current edge in this matchup, primarily because of its strength in momentum and efficiency.

  • +82.7% vs TIL's -78.9%
  • 13.4% ROA vs TIL's -22.4%, ROIC 16.8% vs -18.0%
Best for: momentum and efficiency
DHR
Danaher Corporation
The Income Pick

DHR is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • Dividend streak 9 yrs, beta 0.70, yield 0.7%
  • Lower volatility, beta 0.70, Low D/E 35.1%, current ratio 1.87x
  • Beta 0.70 vs TIL's 1.55, lower leverage
  • 0.7% yield, 9-year raise streak, vs A's 0.8%, (2 stocks pay no dividend)
Best for: income & stability and sleep-well-at-night
A
Agilent Technologies, Inc.
The Growth Play

A is the clearest fit if your priority is growth exposure and valuation efficiency.

  • Rev growth 6.7%, EPS growth 3.2%, 3Y rev CAGR 0.5%
  • PEG 1.46 vs DHR's 35.21
  • Beta 1.06, yield 0.8%, current ratio 1.96x
  • 19.6% margin vs TIL's -1.0%
Best for: growth exposure and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthTIL logoTIL37.2% revenue growth vs ILMN's -0.8%
ValueTMO logoTMOLower P/E (18.9x vs 30.8x)
Quality / MarginsA logoA19.6% margin vs TIL's -1.0%
Stability / SafetyDHR logoDHRBeta 0.70 vs TIL's 1.55, lower leverage
DividendsDHR logoDHR0.7% yield, 9-year raise streak, vs A's 0.8%, (2 stocks pay no dividend)
Momentum (1Y)ILMN logoILMN+82.7% vs TIL's -78.9%
Efficiency (ROA)ILMN logoILMN13.4% ROA vs TIL's -22.4%, ROIC 16.8% vs -18.0%

TIL vs TMO vs ILMN vs DHR vs A — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
TILInstil Bio, Inc.

Segment breakdown not available.

TMOThermo Fisher Scientific Inc.
FY 2025
Consumables
41.9%$18.7B
Service
41.7%$18.6B
Instruments
16.4%$7.3B
ILMNIllumina, Inc.
FY 2025
Sequencing
91.8%$4.0B
Microarray
8.2%$358M
DHRDanaher Corporation
FY 2025
Revenue from Contract with Customer, Measurement, Recurring
81.9%$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring
18.1%$4.4B
AAgilent Technologies, Inc.
FY 2025
Agilent CrossLab
41.9%$2.9B
Life Sciences and Applied Markets
39.2%$2.7B
Applied Markets
18.9%$1.3B

TIL vs TMO vs ILMN vs DHR vs A — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLILMNLAGGINGDHR

Income & Cash Flow (Last 12 Months)

A leads this category, winning 3 of 6 comparable metrics.

TMO and TIL operate at a comparable scale, with $45.2B and $0 in trailing revenue. Profitability is closely matched — net margins range from 19.6% (A) to 14.9% (DHR). On growth, A holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
RevenueTrailing 12 months$0$45.2B$4.4B$24.8B$7.2B
EBITDAEarnings before interest/tax-$54M$10.5B$1.1B$7.2B$1.8B
Net IncomeAfter-tax profit-$47M$6.9B$853M$3.7B$1.4B
Free Cash FlowCash after capex-$34M$6.7B$989M$5.3B$1.3B
Gross MarginGross profit ÷ Revenue+39.4%+67.1%+60.7%+53.0%
Operating MarginEBIT ÷ Revenue+17.8%+20.9%+21.0%+21.5%
Net MarginNet income ÷ Revenue+15.2%+19.4%+14.9%+19.6%
FCF MarginFCF ÷ Revenue+14.9%+22.5%+21.4%+17.4%
Rev. Growth (YoY)Latest quarter vs prior year+6.2%+4.8%+3.7%+10.0%
EPS Growth (YoY)Latest quarter vs prior year+85.6%+11.3%+6.1%+9.8%+60.0%
A leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — TIL and TMO and DHR each lead in 2 of 7 comparable metrics.

At 26.5x trailing earnings, TMO trades at a 26% valuation discount to DHR's 35.7x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.93x vs DHR's 35.21x — a lower PEG means you pay less per unit of expected earnings growth.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
Market CapShares × price$54M$174.4B$24.5B$127.5B$36.7B
Enterprise ValueMkt cap + debt − cash$132M$205.4B$25.6B$141.3B$38.2B
Trailing P/EPrice ÷ TTM EPS-0.74x26.46x29.54x35.73x28.41x
Forward P/EPrice ÷ next-FY EPS est.18.88x30.83x21.34x21.43x
PEG RatioP/E ÷ EPS growth rate12.53x6.98x35.21x1.93x
EV / EBITDAEnterprise value multiple18.86x22.56x18.63x21.64x
Price / SalesMarket cap ÷ Revenue3.91x5.64x5.19x5.28x
Price / BookPrice ÷ Book value/share0.46x3.31x9.22x2.44x5.47x
Price / FCFMarket cap ÷ FCF27.72x26.26x24.23x31.83x
Evenly matched — TIL and TMO and DHR each lead in 2 of 7 comparable metrics.

Profitability & Efficiency

ILMN leads this category, winning 5 of 9 comparable metrics.

ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-40 for TIL. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to ILMN's 0.94x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs TIL's 2/9, reflecting strong financial health.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
ROE (TTM)Return on equity-39.8%+13.2%+32.8%+7.1%+20.8%
ROA (TTM)Return on assets-22.4%+6.4%+13.4%+4.5%+11.1%
ROICReturn on invested capital-18.0%+7.5%+16.8%+5.9%+13.5%
ROCEReturn on capital employed-23.3%+9.1%+17.6%+7.0%+14.5%
Piotroski ScoreFundamental quality 0–926875
Debt / EquityFinancial leverage0.75x0.76x0.94x0.35x0.50x
Net DebtTotal debt minus cash$79M$31.0B$1.1B$13.8B$1.6B
Cash & Equiv.Liquid assets$7M$9.9B$1.4B$4.6B$1.8B
Total DebtShort + long-term debt$85M$40.9B$2.6B$18.4B$3.4B
Interest CoverageEBIT ÷ Interest expense-8.24x5.89x12.09x18.13x15.72x
ILMN leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — ILMN and A each lead in 2 of 6 comparable metrics.

A $10,000 investment in TMO five years ago would be worth $10,136 today (with dividends reinvested), compared to $239 for TIL. Over the past 12 months, ILMN leads with a +82.7% total return vs TIL's -78.9%. The 3-year compound annual growth rate (CAGR) favors A at 3.8% vs TIL's -11.1% — a key indicator of consistent wealth creation.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
YTD ReturnYear-to-date-29.7%-20.7%+19.8%-21.7%-5.5%
1-Year ReturnPast 12 months-78.9%+13.4%+82.7%-11.5%+10.0%
3-Year ReturnCumulative with dividends-29.8%-9.5%-20.4%-13.0%+12.0%
5-Year ReturnCumulative with dividends-97.6%+1.4%-63.4%-15.5%-6.9%
10-Year ReturnCumulative with dividends-98.5%+219.0%+18.6%+222.6%+206.2%
CAGR (3Y)Annualised 3-year return-11.1%-3.3%-7.3%-4.5%+3.8%
Evenly matched — ILMN and A each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ILMN and DHR each lead in 1 of 2 comparable metrics.

DHR is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than TIL's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ILMN currently trades 90.8% from its 52-week high vs TIL's 20.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
Beta (5Y)Sensitivity to S&P 5001.55x0.91x0.99x0.70x1.06x
52-Week HighHighest price in past year$38.50$643.99$177.22$242.80$160.27
52-Week LowLowest price in past year$5.67$385.46$85.77$160.93$108.35
% of 52W HighCurrent price vs 52-week peak+20.6%+72.9%+90.8%+74.2%+81.0%
RSI (14)Momentum oscillator 0–10040.950.866.452.056.1
Avg Volume (50D)Average daily shares traded26K2.0M1.7M4.2M1.9M
Evenly matched — ILMN and DHR each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — DHR and A each lead in 1 of 2 comparable metrics.

Analyst consensus: TMO as "Buy", ILMN as "Buy", DHR as "Buy", A as "Buy". Consensus price targets imply 28.7% upside for DHR (target: $232) vs -5.9% for ILMN (target: $151). For income investors, A offers the higher dividend yield at 0.76% vs TMO's 0.36%.

MetricTIL logoTILInstil Bio, Inc.TMO logoTMOThermo Fisher Sci…ILMN logoILMNIllumina, Inc.DHR logoDHRDanaher Corporati…A logoAAgilent Technolog…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$599.70$151.40$231.80$154.75
# AnalystsCovering analysts42504340
Dividend YieldAnnual dividend ÷ price+0.4%+0.7%+0.8%
Dividend StreakConsecutive years of raises890
Dividend / ShareAnnual DPS$1.69$1.23$0.99
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.7%+3.0%+2.4%+1.2%
Evenly matched — DHR and A each lead in 1 of 2 comparable metrics.
Key Takeaway

A leads in 1 of 6 categories (Income & Cash Flow). ILMN leads in 1 (Profitability & Efficiency). 4 tied.

Best OverallIllumina, Inc. (ILMN)Leads 1 of 6 categories
Loading custom metrics...

TIL vs TMO vs ILMN vs DHR vs A: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TIL or TMO or ILMN or DHR or A a better buy right now?

For growth investors, Agilent Technologies, Inc.

(A) is the stronger pick with 6. 7% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 5x trailing P/E (18. 9x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TIL or TMO or ILMN or DHR or A?

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 5x versus Danaher Corporation at 35. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 46x versus Danaher Corporation's 35. 21x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — TIL or TMO or ILMN or DHR or A?

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +1. 4%, compared to -97. 6% for Instil Bio, Inc. (TIL). Over 10 years, the gap is even starker: DHR returned +222. 6% versus TIL's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TIL or TMO or ILMN or DHR or A?

By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.

70β versus Instil Bio, Inc. 's 1. 55β — meaning TIL is approximately 121% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TIL or TMO or ILMN or DHR or A?

By revenue growth (latest reported year), Agilent Technologies, Inc.

(A) is pulling ahead at 6. 7% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, A leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TIL or TMO or ILMN or DHR or A?

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus 0. 0% for Instil Bio, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: A leads at 21. 3% versus 0. 0% for TIL. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TIL or TMO or ILMN or DHR or A more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 46x versus Danaher Corporation's 35. 21x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 9x forward P/E versus 30. 8x for Illumina, Inc. — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 28. 7% to $231. 80.

08

Which pays a better dividend — TIL or TMO or ILMN or DHR or A?

In this comparison, A (0.

8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. TIL, ILMN do not pay a meaningful dividend and should not be held primarily for income.

09

Is TIL or TMO or ILMN or DHR or A better for a retirement portfolio?

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

70), 0. 7% yield, +222. 6% 10Y return). Instil Bio, Inc. (TIL) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHR: +222. 6%, TIL: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TIL and TMO and ILMN and DHR and A?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DHR, A pay a dividend while TIL, TMO, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.